NASDAQ:TIG - TIGENIX/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$41.98Today's Range$41.98 - $41.9852-Week Range$19.24 - $48.00Volume17,200 shsAverage Volume1,268 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. The company's lead product candidate is the Cx601, which completed Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn's disease. It also engages in developing Cx611, a clinical stage product candidate from its expanded adipose-derived stem cell-based (eASC-based) technology platform, which completed a Phase I study in sepsis and a Phase Ib/IIa trial for the treatment of refractory rheumatoid arthritis; and Cx621, which has completed a Phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. It is also developing AlloCSC-01, a product candidate based on the CSC-based platform, which has completed a Phase I/II study in acute myocardial infarction. The company has operations in Belgium, Spain, and the United States. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium. As of July 3, 2018, TiGenix NV operates as a subsidiary of Takeda Pharmaceutical Company Limited. Receive TIG News and Ratings via Email Sign-up to receive the latest news and ratings for TIG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TIG Previous SymbolNYSE:TIG CUSIPN/A Webwww.tigenix.com Phone321-639-6060Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees80 Outstanding SharesN/AMarket Cap$0.00 OptionableNot Optionable TIGENIX/S (NASDAQ:TIG) Frequently Asked Questions What is TIGENIX/S's stock symbol? TIGENIX/S trades on the NASDAQ under the ticker symbol "TIG." What is the consensus analysts' recommendation for TIGENIX/S? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TIGENIX/S in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TIGENIX/S. Has TIGENIX/S been receiving favorable news coverage? News headlines about TIG stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. TIGENIX/S earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. Who are some of TIGENIX/S's key competitors? Some companies that are related to TIGENIX/S include Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), AgeX Therapeutics (AGE), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aralez Pharmaceuticals (ARLZ), Argos Therapeutics (ARGS), ARMO Biosciences (ARMO), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO) and Egalet (EGLT). Who are TIGENIX/S's key executives? TIGENIX/S's management team includes the folowing people: Dr. Claudia D'Augusta, Chief Financial Officer and Compliance Officer (Age 48)Mr. Wilfried Dalemans, Chief Technical Officer (Age 60)Claudia Jiménez, Sr. Director of Investor Relations & CommunicationsAn Moonen, Gen. Counsel and Company Sec.Dr. Marie Paule Richard, Chief Medical Officer (Age 63) When did TIGENIX/S IPO? (TIG) raised $26 million in an IPO on Thursday, December 15th 2016. The company issued 2,800,000 shares at $9.12 per share. BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of TIGENIX/S? Shares of TIG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is TIGENIX/S's official website? The official website for TIGENIX/S is http://www.tigenix.com. How can I contact TIGENIX/S? TIGENIX/S's mailing address is ROMEINSE STRAAT 12 BOX 2 3001, LEUVEN C9, 3001. The company can be reached via phone at 321-639-6060 or via email at [email protected] MarketBeat Community Rating for TIGENIX/S (NASDAQ TIG)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 178 (Vote Outperform)Underperform Votes: 254 (Vote Underperform)Total Votes: 432MarketBeat's community ratings are surveys of what our community members think about TIGENIX/S and other stocks. Vote "Outperform" if you believe TIG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TIG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/15/2019 by MarketBeat.com StaffFeatured Article: Does the discount rate affect the economy?